Semaglutide Pen 4mg – Adjustable Dose – 2 Pack

Semaglutide is a long acting synthetic GLP-1 receptor agonist with a half-life of approximately 7 days, achieved through fatty acid chain conjugation enabling albumin binding and protection against DPP-4 enzymatic degradation. This 2 pack format supplies two 4mg adjustable dose pens, delivering 8mg total Semaglutide across matched compound batch units. Sitting between the 2mg single adjustable pen and the 9.6mg fixed dose prefilled pen in CSD’s Semaglutide range in terms of total compound supply, while introducing the multi unit pack format as a distinct procurement option for researchers requiring extended supply continuity within the adjustable dose pen format.

The 2 pack format serves a specific research purpose from single pen presentations. For extended Semaglutide research protocols operating across multiple weeks, consistent with the compound’s approximately 7 day half-life and typical once weekly administration schedules. A single 4mg pen may be exhausted mid protocol, introducing a restocking variable that risks compound batch inconsistency between the first and second supply unit. The matched 2 pack eliminates this risk by providing two pens from the same production batch, ensuring compound source consistency across the full protocol timeline. At 4mg per pen the adjustable dose mechanism supports precise titration across the mid range of CSD’s Semaglutide concentration spectrum. Above the 2mg single pen’s lowest entry point and below the 9.6mg fixed dose pen’s higher concentration range.

CSD’s Semaglutide range now spans four distinct presentations: the 2mg adjustable single pen for lowest concentration titration, this 4mg adjustable 2 pack for extended mid range protocol supply, the 9.6mg fixed dose prefilled pen for standardized higher concentration administration, and the 10mg lyophilized vial for reconstitution controlled research applications. The pure GLP-1 receptor selectivity of Semaglutide remains consistent across all four formats, maintaining its position as the single receptor reference standard in CSD’s incretin research family against which dual and triple receptor agonist listings are compared in comparative pathway research.

Every batch of CSD’s Semaglutide pen is third party lab tested for concentration accuracy and purity before being made available, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our Semaglutide range across four formats represents the most complete GLP-1 receptor agonist sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Store at 2–8°C away from direct light. Do not freeze. Keep upright. Intended for research purposes only.

Commonly researched alongside dual and triple incretin agonist compounds in comparative GLP-1 receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.